pharma · HIV-1 Infection · HIV-1 infection
Gilead Sciences
Gilead Sciences Pty Limited
Gilead Sciences clinical programs — 19 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 333 Lakeside Drive, Foster City, CA 94404, US
- Founded
- 1987
- Employees
- 14,602
- Programs
- 30
- Drugs
- 54
- Patents
- 0
Gilead Sciences projects
19 ClinicalTrials.gov programs sponsored by Gilead Sciences.
Gilead Sciences has 19 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CB8025-31731-RE
Gilead Sciences Pty Limited
Primary Biliary Cholangitis
1 trial -
GS-5245 tablets 175 mg, GS-5245 tablets 350 mg
Gilead Sciences Pty Limited
COVID-19
1 trial -
GS-US-174-0144
Gilead Sciences Pty Limited
Hepatitis B Infection
1 trial -
GS-US-528-6727
Gilead Sciences Pty Limited
Human Immunodeficiency Virus (HIV-1) infection
1 trial -
GS-US-563-5925
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
GS-US-563-5926
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
GS-US-577-6153
Gilead Sciences Pty Limited
Non-small cell lung cancer
1 trial -
GS-US-592-6173
Gilead Sciences Pty Limited
PD-L1 Positive Metastatic Triple-Negative Breast Cancer
1 trial -
GS-US-592-6238
Gilead Sciences Pty Limited
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting
1 trial -
GS-US-595-6184
Gilead Sciences Pty Limited
Triple Negative Breast Cancer
1 trial -
GS-US-600-6165
Gilead Sciences Pty Limited
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
GS-US-621-6290
Gilead Sciences Pty Limited
HIV-1 infection
1 trial -
GS-US-621-6463
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
GS-US-626-6216
Gilead Sciences Pty Limited
Metastatic Non–Small Cell Lung Cancer
1 trial -
GS-US-682-6769
Gilead Sciences Pty Limited
Recurrent or Persistent Endometrial Cancer
1 trial -
GS-US-695-6509
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
GS-US-695-7156
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
IMMU-132-13
Gilead Sciences Pty Limited
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1 trial -
Placebo to match 10 mg, Placebo to match 5 mg
Gilead Sciences Pty Limited
Primary Biliary Cholangitis
1 trial
Frequently asked questions
How many clinical projects does Gilead Sciences have?
19 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.